EUVIMEDEUVIMED entdecken
CrossrefInfokarte

AKT is necessary for neuronal hypertrophy and epilepsy caused by Pten knockout

Mackenzi L Prina, Andrew R Goyette, Asan F Abdulkareem, Kamran Tariq, Nathan Burgess, Jianmin Su, Wei Wang, Meijie Li, Lucky L Drucker, Helena H Seo, Nicole M Desmet, Linda Overstreet-Wadiche, Bridget Shafit-Zagardo, Matthew C Weston, Bryan W Luikart

Brain · 2026-11-04 · 149 (11) · 3821-3836

DOI: 10.1093/brain/awag098 ↗
AbstractBibliografische Angaben

Abstract

Abstract Phosphatase and tensin homologue on chromosome 10 (PTEN) is a key negative regulator of the mechanistic target of rapamycin (mTOR) signalling pathway. Mutations in PTEN are highly implicated in autism spectrum disorder, epilepsy, congenital hydrocephaly and macrocephaly. While the conditional genetic knockout of Pten in murine neurons results in hypertrophy, increased migration, excitatory synaptogenesis, hyperexcitability and epileptiform activity, the specific downstream signalling mediators of these pathologies remain to be fully elucidated. Using retroviral-mediated genetic manipulation of individual neurons within the Cre-lox recombination system, we have analysed pathway outputs in response to the manipulation of various genes using immunohistochemistry, confocal microscopy and extensive morphological analyses, alongside whole-cell patch-clamp electrophysiology and 120-h video-EEG monitoring for seizure assessment. Here, we demonstrate that signalling through AKT is necessary for the development of neuronal overgrowth, increased excitatory synapse formation, excessive migration and hyperexcitability fuelled by the loss of PTEN function. Notably, the concurrent deletion of Akt1 and Akt3 isoforms was sufficient to effectively rescue hypertrophic neuronal morphology and physiology. These findings establish AKT as the essential mediator through which PTEN deficiency manifests, providing a transformative therapeutic target to correct the morphological and functional defects central to PTEN-related neurodevelopmental disorders.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →